加载中

    logo
    Effects of laser irradiation on growth factors and cell apoptosis of in vitro cultured infant hemangioma endothelial cells. Zhu Yalin,Wan Xuefeng,Abliz Palidae Life sciences AIMS:The present study aimed to investigate the effects of laser irradiation on the growth factors and cell apoptosis of in vitro cultured infant hemangioma endothelial cells. MAIN METHODS:Endothelial cells of infant hemangioma were cultured in vitro and irradiated using a variable pulse width 1064 nm Nd:YAG laser and intense pulsed light (IPL), the expression of VEGF, VEGFR-2, bFGF and their mRNAs before and after irradiation were measured by ELISA, western blot, RT-PCR and flow cytometry, and changes in the apoptotic rate of endothelial cells in hemangioma were monitored. KEY FINDINGS:The mRNA and protein expressions of VEGF, VEGFR-2, bFGF in hemangioma endothelial cells were inhibited by both Nd:YAG laser and ILP compared to the control cells. The apoptotic rates of hemangioma endothelial cells were also decreased after both laser irradiation treatments in comparison to the blank group. The differences were statistically significant. SIGNIFICANCE:Laser irradiation treats hemangioma not only through a selective photothermal mechanism, but also through cytokine signaling pathways. 10.1016/j.lfs.2019.116685
    Progress in the treatment of infantile hemangioma. Chen Zhao-Yang,Wang Qing-Nan,Zhu Yang-Hui,Zhou Ling-Yan,Xu Ting,He Zhi-Yao,Yang Yang Annals of translational medicine Infantile hemangioma (IH) is a common benign tumor, which mostly resolves spontaneously; however, children with high-risk IH need treatment. Currently, the recognized first-line treatment regimen for IH is oral propranolol, but research on the pathogenesis of IH has led to the identification of new therapeutic targets, which have shown good curative effects, providing more options for disease treatment. This article summarizes the applications of different medications, dosages, and routes of administration for the treatment of IH. In addition to drug therapy, this article also reviews current therapeutic options for IH such as laser therapy, surgical treatment, and observation. To provide the best treatment, therapeutic regimens for IH should be selected based on the child's age, the size and location of the lesion, the presence of complications, the implementation conditions, and the potential outcomes of the treatment. 10.21037/atm.2019.10.47
    Efficacy of propranolol and pingyangmycin, respectively, combined with pulsed dye laser on children with hemangioma. Huang Zhiyong,Zhang Ning,Cai Hanxin,Luo Kunhui Experimental and therapeutic medicine Clinical efficacy of propranolol and pingyangmycin, respectively, combined with pulsed dye laser in the treatment of children with hemangioma was analyzed, to provide a new therapeutic idea for their clinical treatment. A total of 120 children with hemangioma were selected into the study. Children treated with propranolol combined with pulsed dye laser were in group A, those treated with pingyangmycin combined with pulsed dye laser were in group B, and 60 healthy children were selected as control group (group C). Blood samples of children were taken before and after treatment for miR-4295 detection. The expression of miR-4295 was observed after treatment, and the total clinical remission rate and adverse reactions after treatment were compared between the two groups. The tumor volume of the two groups was significantly reduced after treatment, with statistically significant difference (P<0.05); miR-4295 expression was reduced in the two groups (P<0.05); adverse reactions in propranolol group were less than pingyangmycin group during treatment (P<0.05). Propranolol and pingyangmycin, respectively, combined with pulsed dye laser had ideal efficacy on hemangioma in children. Moreover, miR-4295 was highly expressed in children with hemangioma, and the expression level reduced after two methods of treatment. However, adverse reactions in propranolol group were less and its safety was higher. 10.3892/etm.2019.8314
    Oral Propranolol for Infantile Hemangioma. Tozzi Arturo The New England journal of medicine 10.1056/NEJMc1503811
    Safety of Propranolol Therapy for Severe Infantile Hemangioma. Prey Sorilla,Voisard Jean-Jacques,Delarue Alain,Lebbe Geneviève,Taïeb Alain,Leaute-Labreze Christine,Ezzedine Khaled JAMA 10.1001/jama.2015.13969